Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Habte A. Yimer"'
Autor:
Robert M. Rifkin, Saulius K. Girnius, Stephen J. Noga, Ruemu E. Birhiray, Suman Kambhampati, Sudhir Manda, Roger M. Lyons, Habte A. Yimer, Dasha Cherepanov, Eric Lloyd, Presley Whidden, Joshua Richter
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Long-term proteasome inhibitor (PI) treatment can improve multiple myeloma (MM) outcomes, but this can be difficult to achieve in clinical practice due to toxicity, comorbidities, and the burden of repeated parenteral administration. US MM-6
Externí odkaz:
https://doaj.org/article/4610ad81300445efb624a0ed2b1b1a3e
Autor:
Linlin Xu, Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte A. Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul D. Gandhi, Rocco Crescenzo, Kunthel By, Aileen Cohen, Dih-Yih Chen, Adam Idoine, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/1c2ee5ac31c545ed8f557348df39cf33
Autor:
Guillermo Garcia-Manero, Kimo Bachishvili, Elizabeth A. Griffiths, Amer M. Zeidan, Elie Traer, Lalit Saini, Harshad Amin, Sanjay Mohan, Michael Lübbert, Lori Maness-Harris, James M Foran, Dominik Selleslag, Blanca Xicoy Cirici, Daniel Aaron Pollyea, David Sallman, Aref Al-Kali, Jesus Berdeja, Haifa Kathrin Al-Ali, Nancy Y Zhu, Patricia Font Lopez, Guillermo Sanz Santillana, Valeria Santini, Habte A. Yimer, Larry D Cripe, Victor Priego, Olatoyosi Odenike, Bert Heyrman, David Valcarcel, Pankit Vachhani, Yuri Sano, Beloo Mirakhur, Aram Oganesian, Harold Keer, Abdulraheem Yacoub
Publikováno v:
HemaSphere, Vol 7, p e551265b (2023)
Externí odkaz:
https://doaj.org/article/c645340b1872424db531617d804b3c67
Autor:
Saulius K. Girnius, Joshua Richter, Roger M. Lyons, Kimberly Bogard, Sudhir Manda, Ruemu E. Birhiray, Habte A. Yimer, Kim Tran, Suman Kambhampati, Jyoti Arora, Stephen Noga, Robert Rifkin
Publikováno v:
HemaSphere, Vol 7, p e149880d (2023)
Externí odkaz:
https://doaj.org/article/328dc04e4b344064a84c686181fa6753
Autor:
John N. Allan, Javier Pinilla-Ibarz, Douglas E. Gladstone, Krish Patel, Jeff P. Sharman, William G. Wierda, Michael Y. Choi, Susan M. O’Brien, Mazyar Shadman, Matthew S. Davids, John M. Pagel, Habte A. Yimer, Renee Ward, Gary Acton, Pietro Taverna, Daniel L. Combs, Judith A. Fox, Richard R. Furman, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 107, Iss 4 (2021)
Externí odkaz:
https://doaj.org/article/2b83f0254400461d8896d202887eadb7
Autor:
Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu, Jason M Melear, Morton Coleman, Charles M Farber, Jonah Shulman, Emily H Mantovani, Xiaowei Zhang, Aileen Cohen, Jane Huang
Publikováno v:
eJHaem. 4:301-304
Autor:
Jeff P. Sharman, Peter Trask, Yeung-Chul Mun, Anthony Masaquel, Habte A. Yimer, Alexey V. Danilov, John M. Burke, Sunil Babu, Jia Li, Michael Boxer
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:121-128
Introduction: Longitudinal changes in health-related quality of life (HRQoL) are important in patients with chronic lymphocytic leukemia (CLL). GIBB (NCT02320487) is an open-label, single-arm phase II study of obinutuzumab (GA101; G) in combination w
Autor:
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 41, iss 5
PURPOSE Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cebead271e6234bf0b9f19719ee31aa4
https://ruj.uj.edu.pl/xmlui/handle/item/305371
https://ruj.uj.edu.pl/xmlui/handle/item/305371
Autor:
Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Nicole Lamanna, Susan M. O’Brien, Constantine S. Tam, Lugui Qiu, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Tommi Salmi, Megan-Der-Yu Wang, Lina Fu, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman
Publikováno v:
The New England journal of medicine.
In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CL
Autor:
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke, Syed F Zafar, Jamal Misleh, Edwin C Kingsley, Habte A Yimer, Benjamin Freeman, Subramanya S Rao, Arvind Chaudhry, Praveen K Tumula, Mitul D Gandhi, Sudhir Manda, Dih-Yih Chen, Kunthel By, Linlin Xu, Ye Liu, Rocco Crescenzo, Adam Idoine, Xiaoping Zhang, Aileen Cohen, Jane Huang, Jeff P Sharman
Publikováno v:
The Lancet. Haematology. 10(1)
We hypothesised that zanubrutinib, a highly selective next-generation Bruton tyrosine kinase (BTK) inhibitor, would be a safe and active treatment for patients intolerant of ibrutinib, acalabrutinib, or both. We aimed to assess whether zanubrutinib w